Histology of Nerve Tissue

Neuronal Architecture and Function

• Soma (cell body): Contains the nucleus, nucleolus, and rough endoplasmic reticulum (Nissl substance); site of metabolic maintenance and protein synthesis
• Dendrites: Short, branching processes that receive synaptic input; contain free ribosomes, rough ER, and mitochondria; architecture determines integrative capacity
• Axons: Single, elongated projection from the soma; vary in diameter (0.1-100 μm) and length; contain microtubules, neurofilaments, and mitochondria organized longitudinally
• Axon terminal (synaptic bouton): Contains synaptic vesicles filled with neurotransmitters; mitochondria provide ATP for vesicle mobilization and neurotransmitter synthesis
• Myelination: Oligodendrocytes (CNS) and Schwann cells (PNS) wrap around axons to create insulating myelin sheaths; increases conduction velocity via saltatory conduction; unmyelinated fibers are embedded in grooves without wrapping

Glial Cell Categories and Functions

• Star-shaped morphology with numerous processes contacting blood vessels and synapses
• Form the blood-brain barrier (BBB) through tight junctions; regulate extracellular K⁺ and glutamate
• Provide metabolic support via lactate shuttle; release trophic factors (BDNF, NGF)
• Hypertrophic and hyperplastic response to injury (gliosis)

Oligodendrocytes

• CNS myelin-producing cells; each cell myelinates multiple axons (up to 50)
• Vulnerable to hypoxia, toxins, and autoimmune attack (MS pathology)
• Loss results in demyelination and conduction block

Microglia

• Bone marrow-derived CNS immune cells; mesodermal origin distinct from other glia
• Transform from ramified resting state to amoeboid activated state in response to injury/infection
• Phagocytose debris, pathogens, and synapses; produce cytokines (IL-1β, TNF-α)
• Primary effectors in neuroinflammatory diseases

Ependymal cells

• Ciliated epithelial cells lining ventricles; produce cerebrospinal fluid
• Form epithelial barrier between ventricular space and brain parenchyma

• Wrap around single axon segment; produce myelin in PNS
• Support cell body derives from neural crest; provides trophic support
• Migration and proliferation essential for peripheral nerve regeneration

Synaptic Organization

• Synaptic cleft: 20-40 nm space between presynaptic and postsynaptic membranes
• Active zone: Presynaptic membrane specialized for vesicle docking and release
• Postsynaptic density: Electron-dense protein complex anchoring neurotransmitter receptors
• Structural proteins: Cadherins, cell adhesion molecules (CAMs) stabilize synaptic structure
• Synaptic plasticity: Long-term potentiation (LTP) and long-term depression (LTD) involve spine enlargement and receptor trafficking

• Degenerative diseases: Alzheimer disease (neurofibrillary tangles, amyloid plaques), Parkinson disease (Lewy bodies with α-synuclein), frontotemporal dementia (TDP-43 inclusions), ALS (TDP-43 inclusions, motor neuron loss)
• Demyelinating disorders: Multiple sclerosis (oligodendrocyte loss, demyelinated plaques), central pontine myelinolysis (osmotic injury), acute disseminated encephalomyelitis (ADEM)
• Infectious agents: Prions (PrP^sc in Creutzfeldt-Jakob disease), viruses causing encephalitis, bacteria causing meningitis (inflammatory infiltrate with microglial activation), fungal infections
• Neoplastic processes: Gliomas (astrocytoma, oligodendroglioma, glioblastoma), lymphomas (CNS involvement), metastases
• Vascular disease: Ischemic stroke (neuronal necrosis, reactive gliosis), hemorrhage (hemosiderin-laden macrophages), amyloid angiopathy
• Traumatic injury: Diffuse axonal injury (retraction balls), microglial activation, secondary degeneration
• Toxic/metabolic: Alcohol (cerebellar degeneration), chemotherapy (axonal neuropathy), diabetes (node of Ranvier alterations)
• Autoimmune conditions: Neuroinflammation with T-cell and B-cell infiltration, antibodies against synaptic proteins (NMDA receptor, GABA receptor)

Cardinal Symptoms (dependent on anatomical involvement)

• Cognitive decline: Associated with neuronal loss in cortex and hippocampus (dementias); neurofibrillary tangles and amyloid pathology in AD
• Movement disorders: Basal ganglia neuron loss (Parkinson), cerebellar atrophy (ataxias), motor neuron degeneration (ALS)
• Weakness/paralysis: Anterior horn cell loss (motor neurons), demyelination of motor axons, NMJ pathology
• Sensory deficits: Dorsal root ganglion neuron loss, dorsal column demyelination, peripheral axonal loss
• Autonomic dysfunction: Preganglionic and postganglionic neuron loss, fiber loss in autonomic nerves

Physical Examination Findings Correlating with Histology

• Spasticity: Implies upper motor neuron pathology (intact motor axons with demyelination or central tract injury)
• Fasciculations: Visible sign of motor neuron loss with reinnervation; associated with loss of anterior horn cells
• Sensory level (in spinal pathology): Demyelination or axonal loss at specific spinal segment
• Cerebellar atrophy signs: Nystagmus, dysarthria, ataxia correlate with Purkinje cell and granule cell loss
• Cognitive decline with behavioral changes: Frontotemporal dementia with TDP-43 inclusion pathology in prefrontal cortex
• Myoclonic jerks: Associated with prion disease showing spongiform degeneration and gliosis

Tissue Acquisition and Examination Techniques

• Stereotactic or open approach; typically targets lesion on MRI
• Indications: suspected CNS lymphoma, infection, demyelinating disease refractory to therapy, atypical presentations

Lumbar puncture with CSF analysis

• Protein elevation: >100 mg/dL suggests BBB disruption, inflammation, or demyelination
• Cell differential: Lymphocytic predominance (viral, TB, MS exacerbation); neutrophilic predominance (bacterial meningitis); atypical cells (lymphoma); RBCs (subarachnoid hemorrhage)
• Oligoclonal bands: Present in MS (intrathecal immunoglobulin production)

• Intraepidermal nerve fiber (IENF) density <4 fibers/mm diagnostic of small fiber neuropathy
• Immunohistochemistry with PGP9.5 antibody; counts <50% of lower limit normal indicates denervation

• Myelinated fiber loss: Demyelinating (segmental demyelination with onion-bulbing) vs. axonal (axonal degeneration)
• Amyloid deposits: Congo red staining with apple-green birefringence under polarized light
• Vasculitis: Inflammatory infiltrate in vessel walls with fibrinoid necrosis

Histopathological Features by Disease

Neurodegeneration (Alzheimer disease)

• Senile plaques: Extracellular amyloid-β deposits surrounded by dystrophic neurites and microglial response
• Neurofibrillary tangles: Intracellular aggregates of hyperphosphorylated tau
• Neuronal loss and granulovacuolar degeneration in hippocampus and temporal cortex
• Amyloid angiopathy: Amyloid-β deposition in cerebral vessel walls

Demyelinating disease (MS)

• Demyelinated plaques: Loss of myelin with relative preservation of axons (at least initially)
• Gliosis: Astrocytic proliferation and hypertrophy
• Inflammation: CD4+ and CD8+ T-cell infiltration, B-cell accumulation
• Oligodendrocyte loss
• Shadow plaques: Areas of remyelination with thin myelin sheaths

Lewy body disease

• Alpha-synuclein aggregates with ubiquitin and dystrophin
• Lewy bodies: Cytoplasmic inclusions in dopaminergic substantia nigra neurons (Parkinson) and in cortical neurons (Lewy body dementia)

Prion disease (Creutzfeldt-Jakob)

• Spongiform degeneration: Vacuoles of various sizes within neurons and glia
• Gliosis: Astrocytic proliferation
• PrP^sc accumulation detected by immunohistochemistry
• Absence of inflammatory infiltrate (distinguishes from encephalitis)

ALS

• Selective anterior horn cell loss with denervation of motor neuron territory
• TDP-43 inclusions in remaining motor neurons
• Astrocytic and microglial gliosis
• Relatively preserved sensory neurons and dorsal root ganglia

Glioblastoma

• High cellularity with abnormal mitoses
• Microvascular proliferation (hallmark feature)
• Necrosis (pseudopalisading pattern)
• Grade IV tumor with poor prognosis

Staining Techniques and Their Interpretation

Advanced Diagnostic Approaches

Immunofluorescence

• Multiple simultaneous staining: Identify cellular origin (GFAP for astrocytes, Iba-1 for microglia, Olig2 for oligodendrocytes)
• Autoantibody detection: Anti-NMDA receptor, anti-GABA receptor in paraneoplastic syndromes

Flow cytometry (tissue or CSF)

• Distinguish lymphoma from reactive lymphocytosis
• CD4:CD8 ratio abnormalities in specific infections

Genetic testing on tissue

• Identify IDH1/IDH2 mutations (oligodendrogliomas, better prognosis)
• TP53, EGFR amplification (glioblastoma prognostic markers)
• Chromosome 1p/19q codeletion (oligodendroglioma, predicts chemosensitivity)

Disease-Specific Treatment Based on Histology

Demyelinating disease (MS) with demyelinated plaques

• First-line: Disease-modifying therapy (DMT) blocks T-cell migration and reduces inflammation; includes interferon-β, glatiramer acetate, teriflunomide
• Mechanism: Decrease frequency of relapses and reduce new demyelinated plaque formation on MRI
• Acute exacerbation: High-dose IV methylprednisolone (1g daily × 3-5 days) suppresses inflammation and speeds recovery
• Advanced therapies: Fingolimod (sphingosine-1-phosphate receptor modulator), natalizumab (anti-α4 integrin) for escalating disease

Neurodegenerative disease with neuronal loss

• Symptomatic management: No disease-modifying therapy for most (AD, PD)
• Levodopa/carbidopa: Replaces dopamine in Parkinson disease; does not halt neuronal loss in substantia nigra
• Cholinesterase inhibitors (donepezil, rivastigmine): Symptomatic benefit in AD by slowing acetylcholine breakdown; does not prevent neuronal loss
• Amyloid-targeting agents (aducanumab): Monoclonal antibodies against amyloid-β; controversial efficacy
• Tau-targeting approaches: Under investigation; no approved agents yet

Glioblastoma (Grade IV glioma)

• Maximal safe surgical resection reduces tumor burden and improves survival
• Temozolomide chemotherapy: DNA alkylating agent; standard of care with radiation
• Radiation therapy: 60 Gy focal radiation to tumor bed; necessary component of multimodal approach
• Median survival ~14-15 months despite aggressive treatment; reflects high-grade histology

Viral encephalitis with microglial activation and inflammation

• Acyclovir: For HSV encephalitis; inhibits viral DNA replication; must start empirically on clinical suspicion
• Supportive care: Seizure management, ICP monitoring, mechanical ventilation if needed
• Corticosteroids: Controversial in viral encephalitis; may benefit HSV with adjunctive steroid use

• First-line: IV immunoglobulin (IVIG) or plasma exchange (PLEX); removes pathogenic antibodies
• Second-line: Rituximab (anti-CD20 B-cell monoclonal antibody) for B-cell depletion
• Immunosuppression: Mycophenolate mofetil, azathioprine for maintenance
• Tumor screening: Mandatory given frequent paraneoplastic association (ovarian teratoma in young women)

Non-Pharmacological Measures

• Physical therapy: Maintains range of motion in neurodegenerative disease; prevents contractures
• Cognitive rehabilitation: Speech/occupational therapy in dementia and stroke
• Neurorehabilitation: Intensive training promotes neuroplasticity and functional recovery post-stroke
• Genetic counseling: Essential for hereditary neurological diseases (familial AD, SCA, CMT)

Monitoring and Follow-up

• Imaging surveillance: Serial MRI for DMT efficacy in MS (new lesion rate), tumor growth in glioma
• CSF biomarkers: Phosphorylated tau, amyloid-β-42 levels correlate with AD pathology progression
• Functional scales: Modified Rankin scale (stroke), EDSS (MS disability), MMSE or MoCA (cognitive)
• Side effect monitoring: Drug-specific (fingolimod cardiac effects, natalizumab JC virus risk)

Complications of the underlying tissue pathology

• Osmotic demyelination syndrome (central pontine myelinolysis): oligodendrocytes in the basis pontis are exquisitely sensitive to rapid osmotic shift; overly fast correction of chronic hyponatremia produces symmetric pontine myelin loss with axonal sparing. Signals: locked-in syndrome, spastic quadriparesis, or pseudobulbar palsy appearing days after correction. Emergency and largely iatrogenic — US expert consensus limits correction to roughly 8 mEq/L in 24 hours in high-risk patients.
• Mass effect and herniation: glioblastoma, abscess, or HSV encephalitis produce vasogenic edema through blood–brain barrier breakdown; declining consciousness, anisocoria, or Cushing reflex is a neurosurgical emergency.
• Wallerian degeneration and traumatic neuroma: after axotomy the distal segment degenerates while Schwann cells and macrophages clear debris; disordered regeneration into scar yields a painful traumatic neuroma with a positive Tinel sign.
• Onion-bulb hypertrophic neuropathy: repeated Schwann cell demyelination–remyelination cycles (CIDP, CMT1) produce palpably enlarged nerves and progressive weakness.

Complications of treatment

• Natalizumab-associated progressive multifocal leukoencephalopathy: blocked α4-integrin lymphocyte trafficking permits JC virus lysis of oligodendrocytes; new non-enhancing confluent white-matter lesions with subacute deficits. AAN guidance stratifies risk by anti-JCV antibody index, prior immunosuppression, and treatment duration. Emergency — stop drug, consider plasma exchange.
• Fingolimod first-dose bradycardia/AV block: S1P receptor modulation on cardiac myocytes; requires first-dose cardiac observation.
• Amyloid-related imaging abnormalities (ARIA) with anti-amyloid monoclonal antibodies: antibody-mediated clearance destabilizes amyloid-laden vessels, causing edema (ARIA-E) or microhemorrhage (ARIA-H); risk is highest in APOE ε4 homozygotes. Symptomatic ARIA with hemorrhage is an emergency.
• Corticosteroid and chemotherapy toxicity: high-dose methylprednisolone causes hyperglycemia and psychosis; temozolomide causes myelosuppression and Pneumocystis risk.
• Procedural: brain biopsy risks hemorrhage and seizure; lumbar puncture risks post-dural-puncture headache and, with an unrecognized mass lesion, herniation — IDSA advises head CT before LP when focal deficits, papilledema, seizure, altered mentation, or immunocompromise is present.

• One Schwann cell myelinates one internode of one axon; one oligodendrocyte myelinates up to ~50 axons: this ratio explains why a single oligodendrocyte death (MS) knocks out many fibers, while PNS injury is more focal and more repairable.
• Embryologic origins are the classic distractor: Schwann cells are neural crest; oligodendrocytes, astrocytes, and ependymal cells are neuroectoderm; microglia are mesoderm (yolk-sac macrophages). Do not call microglia neuroectodermal.
• Nissl substance is rough ER and is present in soma and dendrites but absent from the axon hillock and axon: after axotomy, central chromatolysis (dispersed Nissl, swollen soma, peripherally displaced nucleus) marks a neuron mounting a regenerative response, while Wallerian degeneration occurs distal to the cut.
• Immunostain associations examiners love: GFAP → astrocytes/astrocytoma; S-100 → Schwann cells/schwannoma and melanoma; Olig2 → oligodendrocyte lineage; Iba-1/CD68 → microglia; PGP9.5 → intraepidermal nerve fibers; Luxol fast blue → myelin.
• Best next step in suspected small fiber neuropathy with burning feet and a normal EMG/nerve conduction study: punch skin biopsy for intraepidermal nerve fiber density — large-fiber studies are normal by definition, so a "normal NCS" does not exclude neuropathy.
• MS plaques show myelin loss with relative axonal preservation early; irreversible disability tracks with later axonal transection. Shadow plaques = remyelination, not new demyelination.
• Peripheral tumor discrimination: schwannoma is S-100 strong, encapsulated, displaces the axon, shows Antoni A/B areas and Verocay bodies; neurofibroma incorporates axons and, when plexiform, points to NF1.
• Saltatory conduction depends on nodal voltage-gated Na⁺ channel clustering: demyelination causes conduction block and slowing with preserved amplitude, whereas axonal loss reduces amplitude — the single distinction that separates demyelinating from axonal neuropathy on nerve conduction studies.